Full Version: Benefits Of Fish Oil
Research studies show fish oil benefits are down right amazing.
And knowing this is the second most important thing you can do for your health. (We'll get to #1 in importance soon.)
Studies are published almost daily as the scientific community discovers more and more of the many extraordinary omega 3 fish oil benefits.
If you haven't already been swept up in the net yet, here are 7 proven omega 3 benefits you should know about.
1. Less Pain and Inflammation. Omega 3 fatty acids, particularly EPA, have a very positive effect on your inflammatory response. Through several mechanisms, they regulate your body's inflammation cycle, which prevents and relieves painful conditions like arthritis, prostatitis, cystitis and anything else ending in "itis."
2. Cardiovascular Health. Omega 3 fatty acids have also been proven to work wonders for your heart and the miles and miles of arteries and veins that make up your cardiovascular system. They help to lower cholesterol, tryglicerides, LDLs and blood pressure, while at the same time increasing good HDL cholesterol. This adds years to your life expectancy.
3. Protection from Stroke and Heart Attack. When plaque builds up on arterial walls and then breaks loose, it causes what's known as a thrombosis, which is a fancy way of saying clot. If a clot gets stuck in the brain, it causes a stroke and when it plugs an artery, it causes a heart attack. Research shows omega 3 fatty acids break up clots before they can cause any damage.
4. Better Brain Function and Higher Intelligence. Pregnant and nursing mothers can have a great impact on the intelligence and happiness of their babies by supplementing with fish oil. For adults, omega 3 improves memory, recall, reasoning and focus. You'll swear you're getting younger and smarter.
5. Less Depression and Psychosis. Making you smarter is not all omega 3 does for your brain. Psychiatry department researchers at the University of Sheffield, along with many other research studies, found that omega 3 fish oil supplements "alleviate" the symptoms of depression, bipolar and psychosis (Journal of Affective Disorder Vol. 48(2-3);149-55).
6. Lower Incidence of Childhood Disorders. Just to show how fish oil fatty acids leave nobody out, studies show that children (and adults) with ADD and ADHD experience a greatly improved quality of life. And those with dyslexia, dyspraxia and compulsive disorders have gotten a new lease on life thanks to omega 3 oils.
7. Reduction of Breast, Colon and Prostate Cancer. And finally, omega 3 fish oil has been shown to help prevent three of the most common forms of cancer – breast, colon and prostate. Science tells us that omega 3s accomplish this in three ways. They stop the alteration from a normal healthy cell to a cancerous mass, inhibiting unwanted cellular growth and causing apoptosis, or cellular death, of cancer cells.
wow very good tips for fish oil.I agree with you.Thanks for sharing. 
work on a biochemical pathway that reduces inflammation. Because so much of our food today enhances inflammation, there is evidence that many of our ailments like heart disease come from an overactive inflammatory response in the body.
Hi Anne Wilson,
I think you have jumped the gun big time here, the study you have mentioned will not be completed until August 2009, you posted this 15th June 2009, are you a fortune teller, can you look into the future or do you have access to other material you forgot to post a link to?
Home Search Study Topics Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
This study is currently recruiting participants.
Verified by University of California, Los Angeles, November 2008
First Received: November 25, 2008 Last Updated: December 2, 2008 History of Changes
Sponsors and Collaborators: University of California, Los Angeles
National Cancer Institute (NCI)
Information provided by: University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00798876
Purpose
Studies on patterns of how many men get prostate cancer in other countries show that environment contributes to the high incidence of prostate cancer in the United States. Epidemiology studies suggest that this influence may be reduced by the diet of men at risk of getting prostate cancer. Although the exact nature of the effects of diet are not completely known, the amount of fat eaten appears to affect the number of men who get prostate cancer. The type of fat also seems to matter. Eating more of a type of fat called omega-3 polyunsaturated fat is associated with decreased prostate cancer risk.
Omega-3 fat comes from fish and is quite different from the type of fat from animals and vegetables (omega-6 fat). Because the exact mechanism of this reduction in prostate cancer risk is not known, no blood test indications, called markers, have been discovered that would show the effect working.
Study doctors designed this study to try to find markers in the blood tests of men who have prostate cancer, and to find out if a diet supplemented with omega-3 type fat from fish oil helps reduce those markers, hence indicating that it helps reduce the cancer in these men. These men will be compared to men with prostate cancer whose diets do not contain the fish-oil fat.
The men chosen will have prostate cancer and be scheduled for operations to have their prostate glands removed. They will be chosen randomly to be given the fish-oil diet or a regular Western diet for comparison for 4 to 8 weeks. Their blood will be checked at the beginning of the diet. After the 4-to-8-week period, they will have their operations. Their blood will be checked again and a sample of their removed prostate will be examined to tell if the diet had any effect on the cancer and its markers.
Condition Intervention
Prostate Cancer
Dietary Supplement: Fish Oil
Dietary Supplement: Vitamin E supplement
Dietary Supplement: Western Diet
Dietary Supplement: Low-Fat Diet
Other: Medical Examination
Other: Dietary Interview
Other: Blood Draw
Procedure: Radical Prostatectomy
Study Type: Interventional
Study Design: Diagnostic, Randomized, Open Label, Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title: Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Resource links provided by NLM:
MedlinePlus related topics: Cancer Dietary Supplements Diets Prostate Cancer
Drug Information available for: alpha-Tocopheryl acetate alpha-Tocopherol Vitamin E Tocopherols Tocotrienol Fish oil
U.S. FDA Resources
Further study details as provided by University of California, Los Angeles:
Primary Outcome Measures:
* To establish and validate intermediate biomarkers for prostate cancer prevention trials by conducting a dietary intervention trial of a low-fat diet with omega-3 fatty acid supplements in men undergoing radical prostatectomy. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
* To establish and validate insulin growth factor-1 (IGF-1) and insulin growth factor binding proteins (IGFBP) as relevant intermediate biomarkers for prostate cancer prevention trials. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
* To establish and validate serum and tissue fatty acids as relevant intermediate biomarkers for prostate cancer prevention trials. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Estimated Enrollment: 70
Study Start Date: August 2005
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Standard Western Diet: Placebo Comparator
Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages.
Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
Dietary Supplement: Western Diet
Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
Other: Medical Examination
Subjects will have a routine medical exam.
Other: Dietary Interview
Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Other: Blood Draw
40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Procedure: Radical Prostatectomy
Subjects will undergo a radical prostatectomy as part of their standard of care.
Low-Fat Diet: Experimental
Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
Dietary Supplement: Fish Oil
Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
Dietary Supplement: Vitamin E supplement
Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
Dietary Supplement: Low-Fat Diet
Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
Other: Medical Examination
Subjects will have a routine medical exam.
Other: Dietary Interview
Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Other: Blood Draw
40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Procedure: Radical Prostatectomy
Subjects will undergo a radical prostatectomy as part of their standard of care.
Detailed Description:
1. To establish and validate intermediate biomarkers for prostate cancer prevention trials by conducting a dietary intervention trial of a low-fat diet with omega-3 fatty acid supplements in men undergoing radical prostatectomy. In initial trials it was feasible to intervene with diet and obtain tissue and serum for bioassay and biomarker development. This aim is to study the effect a low-fat, high omega-3 diet has on serum and tissue biomarkers from patients who have prostatectomies for prostate cancer. Ultimately, we hope to identify and validate intermediate markers of efficacy for large-scale dietary prevention trials.
2. To establish and validate insulin growth factor-1 (IGF-1) and insulin growth factor binding proteins (IGFBP) as relevant intermediate biomarkers for prostate cancer prevention trials. IGF-1 is a peptide growth factor that is important to the growth and progression of prostate cancer. To our knowledge, no prospective dietary intervention studies have evaluated the effect of a low-fat diet with omega-3 fatty acid supplements on IGF-1 and IGFBPs, and their potential to serve as relevant intermediate markers for low-fat dietary intervention trials for prostate cancer prevention.
3. To establish and validate serum and tissue fatty acids as relevant intermediate biomarkers for prostate cancer prevention trials. We will evaluate if men randomized to a low-fat, fish-oil-supplemented diet have increased serum ratios of omega-3:omega-6 fatty acids compared with men randomized to a control Western diet before radical prostatectomy. We also will study if patients in the low-fat, fish oil arm have increased ratios of membrane omega-3:omega-6 fatty acids as well as decreased COX-2 and decreased PGE-2 levels in benign and malignant tissue and in visceral fat. If so, it will proved further evidence to support the potential of low-fat fish oil diets for prostate cancer prevention. If serum omega-3:omega-6 ratios correlate with changes in COX-2 and PGE-2 in tissues, then serum omea-3:omega-6 ratios may be useful for monitoring activity and efficacy of low-fat fish-oil-supplemented diets in future trials.
Eligibility
Ages Eligible for Study: 40 Years to 75 Years
Genders Eligible for Study: Male
Accepts Healthy Volunteers: No
Criteria
Eligibility Criteria:
* Patient consents to participate.
* Medically able to receive and comply with the diet.
* Lives near enough for counseling and follow-up.
* Has elected to have operation to remove prostate.
* Agrees to stop diet or vitamin supplements or herbal supplements for 1 week before the study begins.
* Patient able to stop taking aspirin, COX-2 inhibitors, and other anti-inflammatory medications for 1 week before study start.
* Patient able to safely stop taking fish oil capsules 2 weeks before the diet starts.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00798876
Contacts
Contact: William Aronson, M.D. 310-268-3446 waronson@ucla.edu
Locations
United States, California
UCLA Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: William Aronson, MD 310-268-3446 waronson@ucla.edu
Sub-Investigator: John Glaspy, MD
Sub-Investigator: Pinchas Cohen, MD
West Los Angeles VA Recruiting
Los Angeles, California, United States, 90073
Contact: William Aronson, MD 310-268-3446 waronson@ucla.edu
Sponsors and Collaborators
University of California, Los Angeles
National Cancer Institute (NCI)
Investigators
Principal Investigator: William Aronson, MD UCLA and Western Los Angles VA
More Information
Publications:
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1.
Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol. 1991;30(2):133-40. Review.
Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann GN. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol. 1989 Dec;19(4):319-26. Review.
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991 Jun;63(6):963-6.
Stellman SD, Wang QS. Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites. Cancer. 1994 Feb 15;73(4):1270-5.
Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999 Jan;161(1):152-5.
Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995 May 3;87(9):652-61.
Boyle P, Levi F, Lucchini F, La Vecchia C, Kevi R [corrected to Levi F, Lucchuni F [corrected to Lucchini F. Trends in diet-related cancers in Japan: a conundrum? Lancet. 1993 Sep 18;342(8873):752. No abstract available. Erratum in: Lancet 1993 Oct 16;342(8877):1000.
Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer. 1991 Feb 1;67(3):746-63.
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9.
West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control. 1991 Mar;2(2):85-94.
Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol. 1988 May;127(5):999-1012.
Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L. Dietary fat and prostate cancer progression and survival. Eur Urol. 1999;35(5-6):388-91. Review.
Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995 Oct 4;87(19):1456-62.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989 Apr 1;49(7):1857-60.
Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S, Chien HT, Blot WJ. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res. 1990 Nov 1;50(21):6836-40.
Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000 Jan;71(1 Suppl):179S-88S. Review.
Baghurst KI, Crawford DA, Worsley A, Record SJ. The Victorian Nutrition Survey--intakes and sources of dietary fats and cholesterol in the Victorian population. Med J Aust. 1988 Jul 4;149(1):12-5, 18-20.
Sugano M, Hirahara F. Polyunsaturated fatty acids in the food chain in Japan. Am J Clin Nutr. 2000 Jan;71(1 Suppl):189S-96S. Review.
Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate. 1985;6(4):423-36.
Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, Sandler RS. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):889-95.
Kobayashi M, Sasaki S, Hamada GS, Tsugane S. Serum n-3 fatty acids, fish consumption and cancer mortality in six Japanese populations in Japan and Brazil. Jpn J Cancer Res. 1999 Sep;90(9):914-21.
Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999 Dec;81(7):1238-42.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989 Apr 1;49(7):1857-60.
Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer. 1999 Sep 15;86(6):1019-27.
Zhou JR, Blackburn GL. Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr. 1997 Dec;66(6 Suppl):1572S-1580S. Review.
Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate. 1991;18(3):243-54.
Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 1996 Mar-Apr;16(2):815-20.
Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis. 1988 Apr;9(4):603-5.
Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis. 1988 Apr;9(4):603-5.
Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 1993;22(3):243-52.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89. Review.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998 Jan 23;279(5350):563-6.
Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998 Jun 17;90(12):911-5.
Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997;76(9):1115-8.
Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999 May 1;59(9):2203-9.
Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst. 1999 Mar 17;91(6):512-23.
Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997 Nov 1;57(21):4667-72.
Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res. 1999 Feb-Mar;31(2-3):192-202. Review.
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994 Feb;15(1):80-101. Review.
Donaghy AJ, Baxter RC. Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Baillieres Clin Endocrinol Metab. 1996 Jul;10(3):421-46. Review.
Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997 May;21(5):355-9.
Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab. 1997 Jul;82(7):2177-81.
Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999 Mar;23(3):260-71. Review.
Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000 Apr;183(1):1-9. Review.
Signorello LB, Brismar K, Bergstrom R, Andersson SO, Wolk A, Trichopoulos D, Adami HO. Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst. 1999 Nov 17;91(22):1965-7. No abstract available.
Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, Glaspy JA. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1123-31.
Hansen HS. Dietary essential fatty acids and in vivo prostaglandin production in mammals. World Rev Nutr Diet. 1983;42:102-34. Review. No abstract available.
Karmali RA. Eicosanoids in neoplasia. Prev Med. 1987 Jul;16(4):493-502.
Culp BR, Titus BG, Lands WE. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med. 1979 Nov;3(5):269-78.
Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids. 1992 Oct;27(10):798-803. Review.
Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 1997 Mar;11(4):234-47. Review.
Marnett LJ. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ Health Perspect. 1990 Aug;88:5-12. Review.
Ablin RJ, Shaw MW. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res. 1986 Mar-Apr;6(2):327-8. No abstract available.
Smith BJ, Wills MR, Savory J. Prostaglandins and cancer. Ann Clin Lab Sci. 1983 Sep-Oct;13(5):359-65. Review.
Rubenstein M, Shaw MW, McKiel CF, Ray PS, Guinan PD. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants. Cancer Res. 1987 Jan 1;47(1):178-82.
Shaw MW, Ablin RJ, Ray P, Rubenstein M, Guinan PD, McKiel CF. Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol. 1985 Jul;8(3):77-9.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120. Review.
Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997;75(8):1111-8.
Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000 Jan;42(1):73-8.
Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998 Mar 18;90(6):455-60.
Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40.
Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000 Oct 1;56(4):671-6.
Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000 Aug 1;89(3):589-96.
Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998 Aug 12;77(4):511-5.
Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch MJ. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin. Clin Nephrol. 1999 Feb;51(2):67-72.
Magoha GA. Ten years experience with chronic prostatitis in Africans. East Afr Med J. 1996 Mar;73(3):176-8.
Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986 Jan;27(1):114-20.
Shin BC, Ebner KE, Hudson BG, Carraway KL. Membrane glycoprotein differences between normal lactating mammary tissue and the R3230 AC mammary tumor. Cancer Res. 1975 May;35(5):1135-40.
Feldman JM, Hilf R. A role of estrogens and insulin binding in the dietary lipid alteration of R3230AC mammary carcinoma growth in rats. Cancer Res. 1985 May;45(5):1964-72.
Responsible Party: UCLA ( William Aronson, MD )
Study ID Numbers: 01-07-026, P50 CA 92131-01A1
Study First Received: November 25, 2008
Last Updated: December 2, 2008
ClinicalTrials.gov Identifier: NCT00798876 History of Changes
Health Authority: United States: Institutional Review Board
Study placed in the following topic categories:
Tocopherol acetate
Antioxidants
Genital Neoplasms, Male
Prostatic Diseases
Tocopherol
Trace Elements
Urogenital Neoplasms
Genital Diseases, Male
Hormones
Insulin
Alpha-Tocopherol
Tocopherols
Vitamin E
Tocotrienol
Vitamins
Tocotrienols
Micronutrients
Prostatic Neoplasms
Additional relevant MeSH terms:
Antioxidants
Genital Neoplasms, Male
Prostatic Diseases
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs
Urogenital Neoplasms
Genital Diseases, Male
Protective Agents
Pharmacologic Actions
Neoplasms
Vitamin E
Neoplasms by Site
Vitamins
Micronutrients
Prostatic Neoplasms
ClinicalTrials.gov processed this record on July 21, 2009
Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services
Cheers
I think you have jumped the gun big time here, the study you have mentioned will not be completed until August 2009, you posted this 15th June 2009, are you a fortune teller, can you look into the future or do you have access to other material you forgot to post a link to?
Home Search Study Topics Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
This study is currently recruiting participants.
Verified by University of California, Los Angeles, November 2008
First Received: November 25, 2008 Last Updated: December 2, 2008 History of Changes
Sponsors and Collaborators: University of California, Los Angeles
National Cancer Institute (NCI)
Information provided by: University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00798876
Purpose
Studies on patterns of how many men get prostate cancer in other countries show that environment contributes to the high incidence of prostate cancer in the United States. Epidemiology studies suggest that this influence may be reduced by the diet of men at risk of getting prostate cancer. Although the exact nature of the effects of diet are not completely known, the amount of fat eaten appears to affect the number of men who get prostate cancer. The type of fat also seems to matter. Eating more of a type of fat called omega-3 polyunsaturated fat is associated with decreased prostate cancer risk.
Omega-3 fat comes from fish and is quite different from the type of fat from animals and vegetables (omega-6 fat). Because the exact mechanism of this reduction in prostate cancer risk is not known, no blood test indications, called markers, have been discovered that would show the effect working.
Study doctors designed this study to try to find markers in the blood tests of men who have prostate cancer, and to find out if a diet supplemented with omega-3 type fat from fish oil helps reduce those markers, hence indicating that it helps reduce the cancer in these men. These men will be compared to men with prostate cancer whose diets do not contain the fish-oil fat.
The men chosen will have prostate cancer and be scheduled for operations to have their prostate glands removed. They will be chosen randomly to be given the fish-oil diet or a regular Western diet for comparison for 4 to 8 weeks. Their blood will be checked at the beginning of the diet. After the 4-to-8-week period, they will have their operations. Their blood will be checked again and a sample of their removed prostate will be examined to tell if the diet had any effect on the cancer and its markers.
Condition Intervention
Prostate Cancer
Dietary Supplement: Fish Oil
Dietary Supplement: Vitamin E supplement
Dietary Supplement: Western Diet
Dietary Supplement: Low-Fat Diet
Other: Medical Examination
Other: Dietary Interview
Other: Blood Draw
Procedure: Radical Prostatectomy
Study Type: Interventional
Study Design: Diagnostic, Randomized, Open Label, Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title: Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer
Resource links provided by NLM:
MedlinePlus related topics: Cancer Dietary Supplements Diets Prostate Cancer
Drug Information available for: alpha-Tocopheryl acetate alpha-Tocopherol Vitamin E Tocopherols Tocotrienol Fish oil
U.S. FDA Resources
Further study details as provided by University of California, Los Angeles:
Primary Outcome Measures:
* To establish and validate intermediate biomarkers for prostate cancer prevention trials by conducting a dietary intervention trial of a low-fat diet with omega-3 fatty acid supplements in men undergoing radical prostatectomy. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
* To establish and validate insulin growth factor-1 (IGF-1) and insulin growth factor binding proteins (IGFBP) as relevant intermediate biomarkers for prostate cancer prevention trials. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
* To establish and validate serum and tissue fatty acids as relevant intermediate biomarkers for prostate cancer prevention trials. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Estimated Enrollment: 70
Study Start Date: August 2005
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Standard Western Diet: Placebo Comparator
Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages.
Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
Dietary Supplement: Western Diet
Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
Other: Medical Examination
Subjects will have a routine medical exam.
Other: Dietary Interview
Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Other: Blood Draw
40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Procedure: Radical Prostatectomy
Subjects will undergo a radical prostatectomy as part of their standard of care.
Low-Fat Diet: Experimental
Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
Dietary Supplement: Fish Oil
Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
Dietary Supplement: Vitamin E supplement
Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
Dietary Supplement: Low-Fat Diet
Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
Other: Medical Examination
Subjects will have a routine medical exam.
Other: Dietary Interview
Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Other: Blood Draw
40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
Procedure: Radical Prostatectomy
Subjects will undergo a radical prostatectomy as part of their standard of care.
Detailed Description:
1. To establish and validate intermediate biomarkers for prostate cancer prevention trials by conducting a dietary intervention trial of a low-fat diet with omega-3 fatty acid supplements in men undergoing radical prostatectomy. In initial trials it was feasible to intervene with diet and obtain tissue and serum for bioassay and biomarker development. This aim is to study the effect a low-fat, high omega-3 diet has on serum and tissue biomarkers from patients who have prostatectomies for prostate cancer. Ultimately, we hope to identify and validate intermediate markers of efficacy for large-scale dietary prevention trials.
2. To establish and validate insulin growth factor-1 (IGF-1) and insulin growth factor binding proteins (IGFBP) as relevant intermediate biomarkers for prostate cancer prevention trials. IGF-1 is a peptide growth factor that is important to the growth and progression of prostate cancer. To our knowledge, no prospective dietary intervention studies have evaluated the effect of a low-fat diet with omega-3 fatty acid supplements on IGF-1 and IGFBPs, and their potential to serve as relevant intermediate markers for low-fat dietary intervention trials for prostate cancer prevention.
3. To establish and validate serum and tissue fatty acids as relevant intermediate biomarkers for prostate cancer prevention trials. We will evaluate if men randomized to a low-fat, fish-oil-supplemented diet have increased serum ratios of omega-3:omega-6 fatty acids compared with men randomized to a control Western diet before radical prostatectomy. We also will study if patients in the low-fat, fish oil arm have increased ratios of membrane omega-3:omega-6 fatty acids as well as decreased COX-2 and decreased PGE-2 levels in benign and malignant tissue and in visceral fat. If so, it will proved further evidence to support the potential of low-fat fish oil diets for prostate cancer prevention. If serum omega-3:omega-6 ratios correlate with changes in COX-2 and PGE-2 in tissues, then serum omea-3:omega-6 ratios may be useful for monitoring activity and efficacy of low-fat fish-oil-supplemented diets in future trials.
Eligibility
Ages Eligible for Study: 40 Years to 75 Years
Genders Eligible for Study: Male
Accepts Healthy Volunteers: No
Criteria
Eligibility Criteria:
* Patient consents to participate.
* Medically able to receive and comply with the diet.
* Lives near enough for counseling and follow-up.
* Has elected to have operation to remove prostate.
* Agrees to stop diet or vitamin supplements or herbal supplements for 1 week before the study begins.
* Patient able to stop taking aspirin, COX-2 inhibitors, and other anti-inflammatory medications for 1 week before study start.
* Patient able to safely stop taking fish oil capsules 2 weeks before the diet starts.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00798876
Contacts
Contact: William Aronson, M.D. 310-268-3446 waronson@ucla.edu
Locations
United States, California
UCLA Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: William Aronson, MD 310-268-3446 waronson@ucla.edu
Sub-Investigator: John Glaspy, MD
Sub-Investigator: Pinchas Cohen, MD
West Los Angeles VA Recruiting
Los Angeles, California, United States, 90073
Contact: William Aronson, MD 310-268-3446 waronson@ucla.edu
Sponsors and Collaborators
University of California, Los Angeles
National Cancer Institute (NCI)
Investigators
Principal Investigator: William Aronson, MD UCLA and Western Los Angles VA
More Information
Publications:
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1.
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1.
Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol. 1991;30(2):133-40. Review.
Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann GN. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol. 1989 Dec;19(4):319-26. Review.
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991 Jun;63(6):963-6.
Stellman SD, Wang QS. Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites. Cancer. 1994 Feb 15;73(4):1270-5.
Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999 Jan;161(1):152-5.
Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995 May 3;87(9):652-61.
Boyle P, Levi F, Lucchini F, La Vecchia C, Kevi R [corrected to Levi F, Lucchuni F [corrected to Lucchini F. Trends in diet-related cancers in Japan: a conundrum? Lancet. 1993 Sep 18;342(8873):752. No abstract available. Erratum in: Lancet 1993 Oct 16;342(8877):1000.
Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer. 1991 Feb 1;67(3):746-63.
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9.
West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control. 1991 Mar;2(2):85-94.
Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol. 1988 May;127(5):999-1012.
Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L. Dietary fat and prostate cancer progression and survival. Eur Urol. 1999;35(5-6):388-91. Review.
Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995 Oct 4;87(19):1456-62.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989 Apr 1;49(7):1857-60.
Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S, Chien HT, Blot WJ. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res. 1990 Nov 1;50(21):6836-40.
Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000 Jan;71(1 Suppl):179S-88S. Review.
Baghurst KI, Crawford DA, Worsley A, Record SJ. The Victorian Nutrition Survey--intakes and sources of dietary fats and cholesterol in the Victorian population. Med J Aust. 1988 Jul 4;149(1):12-5, 18-20.
Sugano M, Hirahara F. Polyunsaturated fatty acids in the food chain in Japan. Am J Clin Nutr. 2000 Jan;71(1 Suppl):189S-96S. Review.
Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate. 1985;6(4):423-36.
Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, Sandler RS. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):889-95.
Kobayashi M, Sasaki S, Hamada GS, Tsugane S. Serum n-3 fatty acids, fish consumption and cancer mortality in six Japanese populations in Japan and Brazil. Jpn J Cancer Res. 1999 Sep;90(9):914-21.
Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999 Dec;81(7):1238-42.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989 Apr 1;49(7):1857-60.
Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer. 1999 Sep 15;86(6):1019-27.
Zhou JR, Blackburn GL. Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr. 1997 Dec;66(6 Suppl):1572S-1580S. Review.
Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate. 1991;18(3):243-54.
Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res. 1996 Mar-Apr;16(2):815-20.
Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis. 1988 Apr;9(4):603-5.
Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis. 1988 Apr;9(4):603-5.
Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 1993;22(3):243-52.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89. Review.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998 Jan 23;279(5350):563-6.
Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998 Jun 17;90(12):911-5.
Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 1997;76(9):1115-8.
Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999 May 1;59(9):2203-9.
Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst. 1999 Mar 17;91(6):512-23.
Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997 Nov 1;57(21):4667-72.
Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res. 1999 Feb-Mar;31(2-3):192-202. Review.
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994 Feb;15(1):80-101. Review.
Donaghy AJ, Baxter RC. Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. Baillieres Clin Endocrinol Metab. 1996 Jul;10(3):421-46. Review.
Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997 May;21(5):355-9.
Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab. 1997 Jul;82(7):2177-81.
Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999 Mar;23(3):260-71. Review.
Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000 Apr;183(1):1-9. Review.
Signorello LB, Brismar K, Bergstrom R, Andersson SO, Wolk A, Trichopoulos D, Adami HO. Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst. 1999 Nov 17;91(22):1965-7. No abstract available.
Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, Glaspy JA. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1123-31.
Hansen HS. Dietary essential fatty acids and in vivo prostaglandin production in mammals. World Rev Nutr Diet. 1983;42:102-34. Review. No abstract available.
Karmali RA. Eicosanoids in neoplasia. Prev Med. 1987 Jul;16(4):493-502.
Culp BR, Titus BG, Lands WE. Inhibition of prostaglandin biosynthesis by eicosapentaenoic acid. Prostaglandins Med. 1979 Nov;3(5):269-78.
Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids. 1992 Oct;27(10):798-803. Review.
Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 1997 Mar;11(4):234-47. Review.
Marnett LJ. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ Health Perspect. 1990 Aug;88:5-12. Review.
Ablin RJ, Shaw MW. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res. 1986 Mar-Apr;6(2):327-8. No abstract available.
Smith BJ, Wills MR, Savory J. Prostaglandins and cancer. Ann Clin Lab Sci. 1983 Sep-Oct;13(5):359-65. Review.
Rubenstein M, Shaw MW, McKiel CF, Ray PS, Guinan PD. Immunoregulatory markers in rats carrying Dunning R3327 H, G, or MAT-LyLu prostatic adenocarcinoma variants. Cancer Res. 1987 Jan 1;47(1):178-82.
Shaw MW, Ablin RJ, Ray P, Rubenstein M, Guinan PD, McKiel CF. Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol. 1985 Jul;8(3):77-9.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120. Review.
Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997;75(8):1111-8.
Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000 Jan;42(1):73-8.
Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998 Mar 18;90(6):455-60.
Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40.
Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000 Oct 1;56(4):671-6.
Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000 Aug 1;89(3):589-96.
Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998 Aug 12;77(4):511-5.
Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch MJ. Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin. Clin Nephrol. 1999 Feb;51(2):67-72.
Magoha GA. Ten years experience with chronic prostatitis in Africans. East Afr Med J. 1996 Mar;73(3):176-8.
Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 1986 Jan;27(1):114-20.
Shin BC, Ebner KE, Hudson BG, Carraway KL. Membrane glycoprotein differences between normal lactating mammary tissue and the R3230 AC mammary tumor. Cancer Res. 1975 May;35(5):1135-40.
Feldman JM, Hilf R. A role of estrogens and insulin binding in the dietary lipid alteration of R3230AC mammary carcinoma growth in rats. Cancer Res. 1985 May;45(5):1964-72.
Responsible Party: UCLA ( William Aronson, MD )
Study ID Numbers: 01-07-026, P50 CA 92131-01A1
Study First Received: November 25, 2008
Last Updated: December 2, 2008
ClinicalTrials.gov Identifier: NCT00798876 History of Changes
Health Authority: United States: Institutional Review Board
Study placed in the following topic categories:
Tocopherol acetate
Antioxidants
Genital Neoplasms, Male
Prostatic Diseases
Tocopherol
Trace Elements
Urogenital Neoplasms
Genital Diseases, Male
Hormones
Insulin
Alpha-Tocopherol
Tocopherols
Vitamin E
Tocotrienol
Vitamins
Tocotrienols
Micronutrients
Prostatic Neoplasms
Additional relevant MeSH terms:
Antioxidants
Genital Neoplasms, Male
Prostatic Diseases
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs
Urogenital Neoplasms
Genital Diseases, Male
Protective Agents
Pharmacologic Actions
Neoplasms
Vitamin E
Neoplasms by Site
Vitamins
Micronutrients
Prostatic Neoplasms
ClinicalTrials.gov processed this record on July 21, 2009
Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services
Cheers
Fish Oil has numerous health benefits in human body and the most well known health benefits of fish oil is the source of omega-3 which promote antioxidant, for strong immune and nervous system. That is why most of the natural health products from fish oil are been one of the best to buy from now a days.
Hi Charles Martin,
People will go to extremes to get their fish oil mate.
http://mail.google.com/mail/?account_id=jo...amp;disp=inline
Seriously I agree that fish is great but because you Americans are so unscientific about your arguments a lot of the health benefits you guys attribute to fish oil, and indeed everything else, has not been proven yet. Hype is not proof, it is just selling technique, and you guys fall for it every time. Look at the lady earlier in this post that quoted all of these benefits from a study that hasn't even finished yet, and this type attitude is the prevailing attitude on here.
Everyone makes mistakes, I have made thousands, and some of them by jumping the gun, the very thing I am critical of here, but I didn't do it often, not like you see on here where it is done about everything every day, and a lot of the people do not learn from their mistakes, they make the same mistake daily, they must have been terrible students at school. Health is a subject we should all try to master for our families sake, we don't want to give them bad advice for it may come back to haunt us.
Did you see the book that appeared on New Scientist this week entitled "Unscientific America" they have got a case mate.
Cheers
People will go to extremes to get their fish oil mate.
http://mail.google.com/mail/?account_id=jo...amp;disp=inline
Seriously I agree that fish is great but because you Americans are so unscientific about your arguments a lot of the health benefits you guys attribute to fish oil, and indeed everything else, has not been proven yet. Hype is not proof, it is just selling technique, and you guys fall for it every time. Look at the lady earlier in this post that quoted all of these benefits from a study that hasn't even finished yet, and this type attitude is the prevailing attitude on here.
Everyone makes mistakes, I have made thousands, and some of them by jumping the gun, the very thing I am critical of here, but I didn't do it often, not like you see on here where it is done about everything every day, and a lot of the people do not learn from their mistakes, they make the same mistake daily, they must have been terrible students at school. Health is a subject we should all try to master for our families sake, we don't want to give them bad advice for it may come back to haunt us.
Did you see the book that appeared on New Scientist this week entitled "Unscientific America" they have got a case mate.
Cheers
Hi Shane,
I think you are pretty right here mate, cold water fish have the highest level of omega 3 fatty acids, and that puts sardines, mackerel and atlantic salmon, as well as red salmon from up north at the top of the range, I didn't think albacore was that high I always found it pretty dry when we were canning it, Americans call it chicken of the sea because it is so white and they always can it with spring water, or at least that is the way the did it in the 70's - 80's.
Cheers
I think you are pretty right here mate, cold water fish have the highest level of omega 3 fatty acids, and that puts sardines, mackerel and atlantic salmon, as well as red salmon from up north at the top of the range, I didn't think albacore was that high I always found it pretty dry when we were canning it, Americans call it chicken of the sea because it is so white and they always can it with spring water, or at least that is the way the did it in the 70's - 80's.
Cheers
Fish Liver oil contains mainly fat but it contains many micro nutrients... It is a huge sourse of fat soluble Vitamines such as Vitamines A,D,E,K... Mainly Vit.A & Vit. E. I think no need 2 explain the uses of these vitamines.. U might be already knoing it..
Your thread is really very nice and interesting,i like it.
Thanks for your useful information.Not only that, but you can also get better skin health from fish oil. It has nutrients that will turn your dry, irritated skin into shiny, glowing skin. You may be suffering from a skin disease like eczema, lesions, or rashes, and it can help treat them. If you have psoriasis, you are able to use it topically to relieve the symptoms. Even if you don’t have any abnormal skin condition, regular use will still leave you with more moisture in your skin, making you look both healthier and younger. That can’t be a bad thing.
Hi Guys,
Vitamin A can have toxic effects for pregnant women in large doses, are you confident when you prescribe vitamin A or just following guidelines set down by some manufacturer. Any fat soluble vitamin can accumulate in fatty tissue to dangerous levels.
Cheers
Vitamin A can have toxic effects for pregnant women in large doses, are you confident when you prescribe vitamin A or just following guidelines set down by some manufacturer. Any fat soluble vitamin can accumulate in fatty tissue to dangerous levels.
Cheers
As Fish oil contains contains Omega 3 oils, it is very effective in treating skin problems especially eczema.
Thank you for the article. Full article can be found at;
http://ezinearticles.com/?7-Fish-Oil-Benef...h&id=415032
http://ezinearticles.com/?7-Fish-Oil-Benef...h&id=415032
Hi niki,
Why would you refer readers to that website, Homer Simpson could write those articles and they would have the same amount of credibility, look at the guidelines for people wanting to submit articles, scientific studies does not get mentioned, you understand this don't you.
Try this analogy.... You are accused of doing something illegal, you go to court, the prosecutor starts to invent stories about what you have done for the jury...... wouldn't you prefer that he ( the prosecutor) was made to only tell the truth, and prove that he was telling the truth?
Look at this
EzineArticles - Expert Authors Sharing Their Best Original Articles
Submit Articles
Editorial Guidelines for Submitting To EzineArticles.com
These editorial guidelines are designed to help you understand what we accept and don't accept for inclusion in our article database. Before you submit to our site, we would appreciate if you would please read this page first.
1. EzineArticles.com Editorial Guidelines: (CONTENT QUALIFICATIONS)
To Be Qualified For Our Site, Your Article:
* MUST BE AN ORIGINAL ARTICLE THAT YOU WROTE. If you work for an author as an employee or contractor and are submitting the article, please submit the article as if it was from the original author including his or her email address and name.
* MUST NOT BE AN ARTICLE YOU RIPPED-OFF FROM THE PUBLIC DOMAIN OR BOUGHT (PLR). If you did hire a ghost writer to write your articles, you MUST have an EXCLUSIVE LICENSE that *only* allows your name to be associated with the articles produced for you. Do not waste your time or ours by buying article packs that have non-exclusive licenses as we reject those articles. Why do we do this? #1) It makes you look like a fraud because you're putting your name on someone else's works that already may have hundreds or thousands of other authors who already put their name on the exact same works and #2) we do not want more than one copy of any article in our directory.
* MUST BE informative and share your unique expertise. Include tips, strategies, techniques, case-studies, analysis, opinions and commentary in your articles. We do not accept articles that contain more than 5 lines of quoted or sourced material.
* MUST NOT be a press release, advertisement, sales letter, promotional copy, or blatant and excessive self-promotion or hype.
* MUST HAVE proper English, spelling, grammar, punctuation, capitalization and sentence structure. While we know there is a variation in what is considered "proper English," we ask that you at least be consistent within your article. Your article must also be proofed and double checked for accuracy. If English is your second language, we strongly suggest that you have it proofed by someone who has English as their native tongue before submitting your articles to us.
* SIMPLE PUNCTUATION RULES: One or two spaces after each period, colon, or semi-colon; Periods should be inside of quotes; When doing "..." -- you should use only 3 dots minimum and maximum; When using dashes, use two in a row, ex: "--"; There is never a space BEFORE a period or BEFORE a comma.
* MUST NOT contain: pornography/adult material, hate or violence-oriented, suggest racial intolerance, advocate against any individual or group, have insulting, obscene, degrading tone, or contain profanity.
* MUST NOT contain information on: Hacking/cracking content, bomb creation, support for terrorism/ radicalism/ religious fanaticism, illicit drugs or drug paraphernalia, steroid use or advocacy, weapon/ firearms/ ammunition/ balisongs/ butterfly knives or brass knuckles, or the promotion of hard alcohol/tobacco-related products or prescription drugs.
* MUST NOT contain information that promotes: Term papers or essays for sale to college students, PLR (Private Label Rights) articles as a good thing (it's not), the promotion of email Safe-Lists as a good thing (it's not) or bulk email spamming as a good thing (it's not), advocacy for paid auto-surf programs as a good thing (it's not), advocacy of click fraud or clicking on Adsense ads as a good thing (it's not), advocacy of creating MFA's (Made For Adsense) sites as a good strategy (it's not), or advocacy of Adsense Arbitrage (this policy is created to protect our advertisers interests).
* MUST NOT contain any content that is a violation of any law, be considered defamatory, libelous, or infringes on the legal rights of others.
* MUST NOT be a submission of the exact same article as one that you already submitted. Some authors have submitted the same article multiple times with only a few words changed in the body -- we reject these and ban authors who engage in this practice.
* MUST NOT include a reply to a personal email, letter or other correspondence.
* MUST NOT contain excessive and/or bolded keywords/ phrases. Bolding is limited to headings and subheadings.
Now I ask you wouldn't you have a lot more confidence in an article that was published in PubMed.... that had been checked by experts doing research in the same field (peer reviewed), I know I would.
Cheers
Why would you refer readers to that website, Homer Simpson could write those articles and they would have the same amount of credibility, look at the guidelines for people wanting to submit articles, scientific studies does not get mentioned, you understand this don't you.
Try this analogy.... You are accused of doing something illegal, you go to court, the prosecutor starts to invent stories about what you have done for the jury...... wouldn't you prefer that he ( the prosecutor) was made to only tell the truth, and prove that he was telling the truth?
Look at this
EzineArticles - Expert Authors Sharing Their Best Original Articles
Submit Articles
Editorial Guidelines for Submitting To EzineArticles.com
These editorial guidelines are designed to help you understand what we accept and don't accept for inclusion in our article database. Before you submit to our site, we would appreciate if you would please read this page first.
1. EzineArticles.com Editorial Guidelines: (CONTENT QUALIFICATIONS)
To Be Qualified For Our Site, Your Article:
* MUST BE AN ORIGINAL ARTICLE THAT YOU WROTE. If you work for an author as an employee or contractor and are submitting the article, please submit the article as if it was from the original author including his or her email address and name.
* MUST NOT BE AN ARTICLE YOU RIPPED-OFF FROM THE PUBLIC DOMAIN OR BOUGHT (PLR). If you did hire a ghost writer to write your articles, you MUST have an EXCLUSIVE LICENSE that *only* allows your name to be associated with the articles produced for you. Do not waste your time or ours by buying article packs that have non-exclusive licenses as we reject those articles. Why do we do this? #1) It makes you look like a fraud because you're putting your name on someone else's works that already may have hundreds or thousands of other authors who already put their name on the exact same works and #2) we do not want more than one copy of any article in our directory.
* MUST BE informative and share your unique expertise. Include tips, strategies, techniques, case-studies, analysis, opinions and commentary in your articles. We do not accept articles that contain more than 5 lines of quoted or sourced material.
* MUST NOT be a press release, advertisement, sales letter, promotional copy, or blatant and excessive self-promotion or hype.
* MUST HAVE proper English, spelling, grammar, punctuation, capitalization and sentence structure. While we know there is a variation in what is considered "proper English," we ask that you at least be consistent within your article. Your article must also be proofed and double checked for accuracy. If English is your second language, we strongly suggest that you have it proofed by someone who has English as their native tongue before submitting your articles to us.
* SIMPLE PUNCTUATION RULES: One or two spaces after each period, colon, or semi-colon; Periods should be inside of quotes; When doing "..." -- you should use only 3 dots minimum and maximum; When using dashes, use two in a row, ex: "--"; There is never a space BEFORE a period or BEFORE a comma.
* MUST NOT contain: pornography/adult material, hate or violence-oriented, suggest racial intolerance, advocate against any individual or group, have insulting, obscene, degrading tone, or contain profanity.
* MUST NOT contain information on: Hacking/cracking content, bomb creation, support for terrorism/ radicalism/ religious fanaticism, illicit drugs or drug paraphernalia, steroid use or advocacy, weapon/ firearms/ ammunition/ balisongs/ butterfly knives or brass knuckles, or the promotion of hard alcohol/tobacco-related products or prescription drugs.
* MUST NOT contain information that promotes: Term papers or essays for sale to college students, PLR (Private Label Rights) articles as a good thing (it's not), the promotion of email Safe-Lists as a good thing (it's not) or bulk email spamming as a good thing (it's not), advocacy for paid auto-surf programs as a good thing (it's not), advocacy of click fraud or clicking on Adsense ads as a good thing (it's not), advocacy of creating MFA's (Made For Adsense) sites as a good strategy (it's not), or advocacy of Adsense Arbitrage (this policy is created to protect our advertisers interests).
* MUST NOT contain any content that is a violation of any law, be considered defamatory, libelous, or infringes on the legal rights of others.
* MUST NOT be a submission of the exact same article as one that you already submitted. Some authors have submitted the same article multiple times with only a few words changed in the body -- we reject these and ban authors who engage in this practice.
* MUST NOT include a reply to a personal email, letter or other correspondence.
* MUST NOT contain excessive and/or bolded keywords/ phrases. Bolding is limited to headings and subheadings.
Now I ask you wouldn't you have a lot more confidence in an article that was published in PubMed.... that had been checked by experts doing research in the same field (peer reviewed), I know I would.
Cheers
I read sometime back that fish Oil has numerous health benefits in human body and the most well known health benefits of fish oil is the source of omega-3.
Hello Successfulgirl
The topic sure changed course . . .
You may like to check out this article titled 'Health Benefits of Omega 3 Fatty Acids':
http://www.healthcastle.com/omega3.shtml
Enjoy the read,
Tracey
The topic sure changed course . . .
You may like to check out this article titled 'Health Benefits of Omega 3 Fatty Acids':
http://www.healthcastle.com/omega3.shtml
Enjoy the read,
Tracey
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.